Clinical Trial Update: Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating ruxolitinib as first-line therapy for primary haemophagocytic lymphohistiocytosis and is currently recruiting in France.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophagocytic Lymphohistiocytosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Haemophagocytic Lymphohistiocytosis | Phase 2 | Status: RECRUITING